Olmat MT Tablets (Olmesartan +Metoprolol )

• Composition :
  Each tablet contains Olmesartan 20mg and Metoprolol 25mg / 50mg.
• Indications :
  It is used in the treatment of essential hypertension
• Pharmacodynamics :
  Olmesartan is a selective angiotensin II receptor antagonist. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in the vascular smooth muscle. Metoprolol is a beta 1-selective (cardioselective) adrenergic receptor blocking agent. Beta-blocking activity of metoprolol is shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia and (4) reduction of reflex orthostatic tachycardia.
• Dosage and administration :
  One tablet a day to be taken with food.
• Contraindications :
  Contraindicated in severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place) and in patients who are hypersensitive to any component of this product.
• Precautions and warnings :
  Olmesartan- Observe for signs and symptoms of hypotension in patients with an activated renin-angiotensin aldosterone system, Monitor for worsening renal function in patients with renal impairment.Metoprolol-Worsening cardiac failure may occur, it may be necessary to lower the dose of metoprolol or temporarily discontinue it. Use with caution in patients with impaired hepatic function. In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent. May mask tachycardia occurring with hypoglycemia. Beta-blockers should be avoided in patients with bronchospastic disease.
• Use in pregnancy, lactation & pediatrics :
  Not recommended for use in pregnancy. Avoid use in lactating women. Safety and efficacy has not been established in pediatric patients.
• Drug interactions :
  Olmesartan- used concomitantly with NSAIDs use may lead to increased risk of renal impairment and loss of antihypertensive effect. Metoprolol- Catecholamine-depleting drugs (eg, reserpine, mono amine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents.CYP2D6 Inhibitors are likely to increase metoprolol concentration. Concomitant use of glycosides, clonidine, and diltiazem and verapamil with beta-blockers can increase the risk of bradycardia.
• Adverse reactions :
  Headache, dizziness, depression, fatigue, shortness of breath, bradycardia, hypotension, nausea, diarrhea, pruritis and rash.
• Therapy Area :
  Anti-Hypertensives